FASEB J.
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Gershoni, J. M.
Right arrow Articles by Buyaner, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Gershoni, J. M.
Right arrow Articles by Buyaner, D.

The FASEB Journal, Vol 7, 1185-1187, Copyright © 1993 by The Federation of American Societies for Experimental Biology

RESEARCH COMMUNICATIONS

HIV binding to its receptor creates specific epitopes for the CD4/gp120 complex

JM Gershoni, G Denisova, D Raviv, NI Smorodinsky and D Buyaner
Department of Cell Research and Immunology, George S. Wise Faculty of Life Sciences, Tel Aviv University, Israel.

Effective vaccines against the human immunodeficiency virus (HIV) must cope with the genetic variation of the viral envelope (gp120) to combat or prevent acquired immunodeficiency syndrome (AIDS). Here we describe novel epitopes that are accentuated when gp120 complexes with its receptor (CD4). The presentation of these epitopes results through conformational rearrangements in the CD4/gp120 complex. Monoclonal antibodies directed to these epitopes inhibit syncytium formation, thus indicating the potential use of these epitopes as subunit vaccines.


This article has been cited by other articles:


Home page
 FASEB J.Home page
E. M. Bublil, S. Yeger-Azuz, and J. M. Gershoni
Computational prediction of the cross-reactive neutralizing epitope corresponding to the monoclonal antibody b12 specific for HIV-1 gp120
FASEB J, September 1, 2006; 20(11): 1762 - 1774.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
M. Khati, M. Schuman, J. Ibrahim, Q. Sattentau, S. Gordon, and W. James
Neutralization of Infectivity of Diverse R5 Clinical Isolates of Human Immunodeficiency Virus Type 1 by gp120-Binding 2'F-RNA Aptamers
J. Virol., December 1, 2003; 77(23): 12692 - 12698.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
T. Fouts, K. Godfrey, K. Bobb, D. Montefiori, C. V. Hanson, V. S. Kalyanaraman, A. DeVico, and R. Pal
Crosslinked HIV-1 envelope-CD4 receptor complexes elicit broadly cross-reactive neutralizing antibodies in rhesus macaques
PNAS, September 3, 2002; 99(18): 11842 - 11847.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. Moulard, S. K. Phogat, Y. Shu, A. F. Labrijn, X. Xiao, J. M. Binley, M.-Y. Zhang, I. A. Sidorov, C. C. Broder, J. Robinson, et al.
Broadly cross-reactive HIV-1-neutralizing human monoclonal Fab selected for binding to gp120-CD4-CCR5 complexes
PNAS, May 14, 2002; 99(10): 6913 - 6918.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
D. H. Margolin, E. F. Helmuth Saunders, B. Bronfin, N. de Rosa, M. K. Axthelm, X. Alvarez, and N. L. Letvin
High Frequency of Virus-Specific B Lymphocytes in Germinal Centers of Simian-Human Immunodeficiency Virus-Infected Rhesus Monkeys
J. Virol., March 19, 2002; 76(8): 3965 - 3973.
[Abstract] [Full Text] [PDF]

Home page
 BloodHome page
D. Misse, P.-O. Esteve, B. Renneboog, M. Vidal, M. Cerutti, Y. St Pierre, H. Yssel, M. Parmentier, and F. Veas
HIV-1 glycoprotein 120 induces the MMP-9 cytopathogenic factor production that is abolished by inhibition of the p38 mitogen-activated protein kinase signaling pathway
Blood, August 1, 2001; 98(3): 541 - 547.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
T. R. Fouts, R. Tuskan, K. Godfrey, M. Reitz, D. Hone, G. K. Lewis, and A. L. DeVico
Expression and Characterization of a Single-Chain Polypeptide Analogue of the Human Immunodeficiency Virus Type 1 gp120-CD4 Receptor Complex
J. Virol., December 15, 2000; 74(24): 11427 - 11436.
[Abstract] [Full Text]

Home page
 ScienceHome page
R. A. LaCasse, K. E. Follis, M. Trahey, J. D. Scarborough, D. R. Littman, and J. H. Nunberg
Fusion-Competent Vaccines: Broad Neutralization of Primary Isolates of HIV
Science, January 15, 1999; 283(5400): 357 - 362.
[Abstract] [Full Text]

Home page
 J. Virol.Home page
N. M. Stamatos, J. R. Mascola, V. S. Kalyanaraman, M. K. Louder, L. M. Frampton, D. L. Birx, and T. C. VanCott
Neutralizing Antibodies from the Sera of Human Immunodeficiency Virus Type 1-Infected Individuals Bind to Monomeric gp120 and Oligomeric gp140
J. Virol., December 1, 1998; 72(12): 9656 - 9667.
[Abstract] [Full Text] [PDF]

Home page
 J. Virol.Home page
N. Sullivan, Y. Sun, Q. Sattentau, M. Thali, D. Wu, G. Denisova, J. Gershoni, J. Robinson, J. Moore, and J. Sodroski
CD4-Induced Conformational Changes in the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein: Consequences for Virus Entry and Neutralization
J. Virol., June 1, 1998; 72(6): 4694 - 4703.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1993 by The Federation of American Societies for Experimental Biology.